Valuation: Mylan N.V.

Market Cap 19.12B 16.57B 15.66B 14.22B 26.65B 1,835B 26.81B 187B 72.26B 931B 71.84B 70.24B 2,966B P/E 2026 *
53.6x
P/E 2027 * 32.5x
Enterprise Value 31.19B 27.03B 25.55B 23.19B 43.47B 2,992B 43.73B 305B 118B 1,518B 117B 115B 4,837B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 2.01x
Free-Float
91.44%
Yield 2026 *
3.06%
Yield 2027 * 3.13%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 19.12B
+0.15%+1.21%+48.79%+99.17% 1,013B
+0.03%+0.07%+51.47%+64.51% 644B
-0.20%+4.62%+21.39%+70.53% 465B
+0.53%+3.42%+39.21%+38.70% 352B
+0.39%+2.22%+17.02%+23.87% 264B
+0.17%+2.19%+6.33%+10.93% 253B
+0.19%-3.81%+37.81%+43.02% 203B
-1.20%-6.64%-23.23%-59.10% 188B
+0.94%+1.39%+33.21%+95.29% 181B
Average +0.40%-1.08%+25.78%+42.99% 395.97B
Weighted average by Cap. +0.34%+0.01%+34.15%+59.58%

Financials

2026 *2027 *
Net sales 14.79B 12.81B 12.11B 10.99B 20.61B 1,418B 20.73B 145B 55.87B 719B 55.54B 54.31B 2,293B 15.05B 13.04B 12.33B 11.19B 20.98B 1,444B 21.1B 147B 56.87B 732B 56.54B 55.29B 2,335B
Net income 221M 191M 181M 164M 308M 21.18B 310M 2.16B 834M 10.74B 829M 811M 34.24B 407M 353M 333M 302M 567M 39.02B 570M 3.98B 1.54B 19.79B 1.53B 1.49B 63.09B
Net Debt 12.07B 10.46B 9.88B 8.97B 16.81B 1,157B 16.92B 118B 45.59B 587B 45.32B 44.32B 1,871B 11.08B 9.6B 9.07B 8.24B 15.44B 1,063B 15.53B 108B 41.86B 539B 41.62B 40.69B 1,718B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!